Cancer Chemotherapy and Pharmacology

, Volume 71, Issue 6, pp 1629–1634 | Cite as

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer

Original Article



Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation.


Enrolled patients received ADT in the form of leuprolide every 12 weeks for 24 months with bicalutamide initiating after the completion of chemotherapy. Chemotherapy consisted of ketoconazole and doxorubicin for weeks 1, 3, and 5 and estramustine and docetaxel and for weeks 2, 4 and 6. During weeks 7 and 8, no treatment was received.


Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %).


The treatment demonstrated clinical benefit in all patient subsets with minimal reversible treatment-related adverse events. Subgroup analysis suggests that having prior local therapy resulted in greater PFS and OS.


Androgen deprivation Castration-resistant prostate cancer Chemotherapy Hormone therapy 


  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29PubMedCrossRefGoogle Scholar
  2. 2.
    Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325–1332PubMedCrossRefGoogle Scholar
  3. 3.
    Pacholke HD, Wajsman Z, Algood CB, Morris CG, Zlotecki RA (2004) Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival. Urology 64(5):982–986PubMedCrossRefGoogle Scholar
  4. 4.
    Stephenson AJ, Eastham JA (2005) Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23(32):8198–8203PubMedCrossRefGoogle Scholar
  5. 5.
    Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(18):1156–1161PubMedCrossRefGoogle Scholar
  6. 6.
    Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR (1992) The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147(3 Pt 2):956–961PubMedGoogle Scholar
  7. 7.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597PubMedCrossRefGoogle Scholar
  8. 8.
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D’Amico AV (2005) Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23(28):6992–6998PubMedCrossRefGoogle Scholar
  9. 9.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439PubMedCrossRefGoogle Scholar
  10. 10.
    Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J et al (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12(4):683–688PubMedGoogle Scholar
  11. 11.
    Amato RJ, Ellerhorst J, Bui C, Logothetis CJ (1995) Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1(4):168–172PubMedCrossRefGoogle Scholar
  12. 12.
    Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC et al (1997) Phase II trial of alternating weekly chemotherapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3(12 Pt 1):2371–2376PubMedGoogle Scholar
  13. 13.
    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527PubMedCrossRefGoogle Scholar
  14. 14.
    Bagley C, Lane R, Blasko J, Grimm P, Cobb O, Ragde H (eds) (2000) Adjuvant chemotherapy and hormonal therapy of high risk prostate cancer. 2000 ASCO Annual MeetingGoogle Scholar
  15. 15.
    Osborne CK, Blumenstein B, Crawford ED, Coltman CA, Smith AY, Lambuth BW et al (1990) Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest oncology group study. J Clin Oncol 8(10):1675–1682PubMedGoogle Scholar
  16. 16.
    Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J et al (2005) Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 23(15):3352–3357PubMedCrossRefGoogle Scholar
  17. 17.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520PubMedCrossRefGoogle Scholar
  18. 18.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512PubMedCrossRefGoogle Scholar
  19. 19.
    Amato RJ, Teh BS, Henary H, Khan M, Saxena S (2009) A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol 27(2):165–169PubMedCrossRefGoogle Scholar
  20. 20.
    Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148–1159PubMedCrossRefGoogle Scholar
  21. 21.
    Srinivas S, King C, Colocci N, Brooks J, Gill H, J. P (eds) (2006) Adjuvant docetaxel chemotherapy with abbreviated hormonal therapy in patients with high-risk prostate cancer. 2006 Prostate Cancer SymposiumGoogle Scholar
  22. 22.
    Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA et al (2008) Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26(36):5936–5942PubMedCrossRefGoogle Scholar
  23. 23.
    Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E et al (2005) Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 23(12):2789–2796PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Robert Amato
    • 1
  • Mika Stepankiw
    • 2
  • Patricia Gonzales
    • 2
  1. 1.Division of Oncology, Department of Internal MedicineUniversity of Texas Health Science Center at Houston (Medical School)/Memorial Hermann Cancer CenterHoustonUSA
  2. 2.University of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations